Skip to content
StockMarketAgent
Direct answer
PEP trades against a final fair-value range of $142.66-$206.45, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $143, high $206, with mid-point at $174.
Stock analysis

PEP PepsiCo Inc. fair value $174–$206

PEP
By StockMarketAgent.AI team· supervised by
Проанализировано: 2026-05-08Следующее обновление: 2026-08-08Methodology v2.4Archetype: Mature dividendNASDAQ · Consumer Staples
View archive
Цена
$154.62
▲ +19.79 (+12.80%)
Справедливая стоимость
$174
$174–$206
Рекомендация
Покупать
confidence 88/100
Потенциал роста
+12.8%
upside to fair value
Запас прочности
$148.25
buy below · 15%
Капитализация
$211.4B
P/E fwd 16.9
Английский по умолчаниюRU
Показываем английский источник, пока идёт перевод
Этот отчёт ещё не переведён. Обновите страницу через несколько минут, когда очередь переводов его обработает.

§1 Краткое резюме

  • Composite fair value $174 with high case $206.
  • Implied upside of 12.8% to fair value.
  • Moat 9/10 · confidence 88/100 · Mature dividend.
  • Trades at a measured discount to fair value with adequate margin of safety.
Fair value
$174
Margin of safety
+11.3%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$154.62Price
FV $174.41
High $206.45

PEP trades against a final fair-value range of $142.66-$206.45, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Deep global distribution networks covering
    Deep global distribution networks covering developed and emerging markets.
  • Immense brand equity and pricing
    Immense brand equity and pricing power across both beverage and snack portfolios.
  • Bull thesis
    Valuation synthesis intentionally anchors heavily on Forward Earnings to mitigate terminal value dominance.

§2 Медвежий сценарий

A sustained macroeconomic downturn coupled with accelerated adoption of GLP-1 weight-loss drugs leads to structural volume declines and an inability to offset cost inflation through pricing, heavily compressing operating margins and driving free cash flow below historical norms.

Как может разрушиться эта теза

GLP-1 Widespread Adoption

· Medium

Mass adoption of appetite-suppressing GLP-1 drugs permanently reduces per-capita consumption of high-calorie snacks and sugary beverages, breaking historical volume baselines.

FV impact
-25%
Trigger
3-5 years

Total Loss of Pricing Power

· Low

Consumer fatigue over successive price hikes forces aggressive discounting and promotional activity to defend market share against private label brands, destroying gross margins.

FV impact
-20%
Trigger
1-2 years

Supply Chain and Input Cost Shock

· Medium

Extreme agricultural commodity inflation and localized supply chain disruptions structurally elevate the cost base beyond what can be passed to consumers, permanently compressing operating margins.

FV impact
-15%
Trigger
1-3 years
Сигналы раннего предупреждения для мониторинга
МетрикаТекущееТриггерный порог
Consecutive quarters of negative organic volume growth.MonitorDeterioration versus the report thesis
Gross margin compression exceeding 150 basis points.MonitorDeterioration versus the report thesis
Substantial shift in market share to private label brands.MonitorDeterioration versus the report thesis
Significant downward revisions in forward consensus earnings.MonitorDeterioration versus the report thesis
Unplanned increases in promotional spend to clear inventory.MonitorDeterioration versus the report thesis

§3 Финансовая история

Отчёт о прибылях — последние шесть периодов
СтатьяT−0T−1T−2T−3CAGR
Период2022-12-312023-12-312024-12-312025-12-31Trend
Выручка$86.39B$91.47B$91.85B$93.93B+2.8%
Валовая прибыль$45.82B$49.59B$50.11B$50.86B+3.5%
Операционная прибыль$11.36B$12.91B$12.92B$13.49B+5.9%
Чистая прибыль$8.91B$9.07B$9.58B$8.24B-2.6%
EPS (разводнённая)$6.42$6.56$6.95$6.00-2.2%
EBITDA$14.92B$15.75B$16.68B$15.54B+1.4%
R&D
SG&A$34.46B$36.68B$37.19B$37.37B+2.7%

Баллы качества

F-балл Пиотроски
5 / 9
Сводный балл качества 0–9
Z-балл Альтмана
3.59
Риск банкротства (>3 безопасно)
M-балл Бениша
-2.56
Риск манипуляций с прибылью
OCF / Чистая прибыль
1.47×
>1 указывает на высокое качество прибыли
Фильтр качества учёта
Pass
Фильтр с учётом сектора
ROIC
12.8%
Доходность инвестированного капитала
Раздел 3

Numbers analysis

Распределение капитала

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Индивидуальные подписчики — с §4ещё 11 разделов

Прочитайте полный анализ — ещё 11 разделов.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Полный отчёт по каждому покрываемому тикеру
Архив рекомендаций за 24 месяца
Брифинги списка наблюдения и алерты по изменению рекомендаций
Экспорт в PDF и DOCX на любом языке
Начать пробный период
Отмена в любое время.
FAQ

PEP — frequently asked questions

  1. Based on our latest analysis, PEP looks modestly undervalued. The current price is $155 versus a composite fair-value midpoint of $174 (range $143–$206), which implies roughly 12.8% upside to the midpoint.
Related coverage

Names readers of PEP also follow

Same archetype: mature-dividend
Same sector: Consumer Staples